Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Platelet count: Longitudinal platelet counts (routine visits, hospitalizations) will be extracted. • Using group based trajectory modeling or latent class mixed models, patients will be assigned to data driven platelet trajectory classes, anticipated as: 1. Stable normal (no thrombocytopenia) 2. Transient thrombocytopenia (recovery to normal) 3. Intermittent/fluctuating thrombocytopenia 4. Persistent mild-moderate thrombocytopenia (e.g., 50-149×10⁹/L) 5. Persistent severe thrombocytopenia (\<50×10⁹/L)

Study summary

Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.

Eligibility

Primary outcome measure(s)

• All-cause mortality — From date of diagnosis until the date of death from any cause,assessed up to 5 years"

Trial sites (1)

More New Valley University trials in Egypt

Other trials for the same condition